| Literature DB >> 26119873 |
Benjamin T Dodsworth1, Rowan Flynn1, Sally A Cowley1.
Abstract
Naïve or ground state pluripotency is a cellular state in vitro which resembles cells of the preimplantation epiblast in vivo. This state was first observed in mouse embryonic stem cells and is characterized by high rates of proliferation, the ability to differentiate widely, and global hypomethylation. Human pluripotent stem cells (hPSCs) correspond to a later or "primed" stage of embryonic development. The conversion of hPSCs to a naïve state is desirable as their features should facilitate techniques such as gene editing and more efficient differentiation. Here we review protocols which now allow derivation of naïve human pluripotent stem cells by transgene expression or the use of media formulations containing inhibitors and growth factors and correlate this with pathways involved. Maintenance of these ground state cells is possible using a combination of basic fibroblast growth factor and human leukemia inhibitory factor together with dual inhibition of glycogen synthase kinase 3 beta, and mitogen-activated protein kinase kinase (MEK). Close similarity between the ground state hPSC and the in vivo preimplantation epiblast have been shown both by demonstrating similar upregulation of endogenous retroviruses and correlation of global RNA-seq data. This suggests that the human naïve state is not an in vitro artifact.Entities:
Keywords: Differentiation; Embryonic stem cells; Ground state; Naïve; Pluripotency
Mesh:
Year: 2015 PMID: 26119873 PMCID: PMC4833179 DOI: 10.1002/stem.2085
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277
Figure 2Effects of naïve conversion strategies on the core naïve pluripotency network. Components directly driving naivety are presented in green, whereas components with naïve repressive function are shown as red. Thick arrows indicate several publications have reported this interaction independently. External components present in conversion media of different protocols are color coded. All protocols require addition of a GSK3β inhibitor: The Theunissen et al. protocol uses IM‐12 19, the Chan et al. protocol BIO 17, whereas all other protocols use CHIR99021. KLF2 and NANOG are overexpressed in the protocol developed by Takashima et al. 14, which is depicted by a halo around these transcription factors. TGFβ is used as a supplement by Gafni et al. 15 and is present in the basal media of the protocol devised by Chan et al. 17. The PKC inhibitor Gö6983 is optional in the protocol by Gafni et al. 15. Abbreviations used: BIRB, BIRB796; CHIR, CHIR99021; FGF4, fibroblast growth factor; Go, Gö6983; GSK3, glycogen synthase kinase 3; HDAC, histone deacetylase; hLIF, human leukemia inhibitory factor; PD17, PD173074; PD03, PD0325901; SB59, SB590885; SP6, SP600125; TGFβ, transforming growth factor beta 14, 16, 17, 18, 19, 20, 32, 37, 38, 39.